Tian Chunyuan, Li Xing, Yuan Xingxing, Li Zhuying
Department of Graduate School, Heilongjiang University of Chinese Medicine Harbin 150040, Heilongjiang, China.
Department of Respiratory Medicine, The First Affiliated Hospital, Heilongjiang University of Chinese Medicine Harbin 150040, Heilongjiang, China.
Am J Transl Res. 2024 Nov 15;16(11):6289-6302. doi: 10.62347/OSNZ1705. eCollection 2024.
The respiratory microbiota significantly influence the onset and progression of asthma, as underscored by recent studies revealing discernible differences between asthma patients and healthy individuals. This review delves into the relationship between respiratory microbiota and asthma, with a particular emphasis on possible therapeutic targets and emerging treatments. Existing research is thoroughly synthesized, illuminating the association between microbial communities and the incidence of asthma. In addition to antibiotic therapy, attention is directed towards modulating the immune balance within the respiratory microbiota as a promising therapeutic approach. Specifically, the role of immunomodulators targeting key immune pathways, such as interleukins and cytokines implicated in asthma pathogenesis, is examined. Furthermore, the regulation of the gut-lung axis is explored, highlighting the significance of the gut microbiota in shaping systemic immune responses and respiratory health. Moreover, the potential of immune cell modulation as a therapeutic avenue is explored, focusing on targeting specific immune cell populations involved in asthma pathophysiology. Future research directions and challenges are also addressed, underscoring the need for a deeper understanding of the intricate interplay between respiratory microbiota and the pathogenesis of asthma.
近期研究表明哮喘患者与健康个体之间存在明显差异,这凸显了呼吸道微生物群对哮喘发病和进展的显著影响。本综述深入探讨了呼吸道微生物群与哮喘之间的关系,特别强调了可能的治疗靶点和新兴治疗方法。对现有研究进行了全面综合,阐明了微生物群落与哮喘发病率之间的关联。除了抗生素治疗外,调节呼吸道微生物群内的免疫平衡作为一种有前景的治疗方法也受到关注。具体而言,研究了针对关键免疫途径的免疫调节剂的作用,如参与哮喘发病机制的白细胞介素和细胞因子。此外,还探讨了肠-肺轴的调节,强调了肠道微生物群在塑造全身免疫反应和呼吸道健康方面的重要性。此外,还探索了免疫细胞调节作为一种治疗途径的潜力,重点是针对参与哮喘病理生理学的特定免疫细胞群体。还讨论了未来的研究方向和挑战,强调需要更深入地了解呼吸道微生物群与哮喘发病机制之间的复杂相互作用。